C08B37/08

METHODS OF CONVERTING BIOMASS NUCLEIC ACIDS AND CONVERTED BIOMASS NUCLEIC ACID PRODUCTS AND USES THEREOF
20210355246 · 2021-11-18 ·

Crosslinked nucleotide polymers. A crosslinked nucleotide polymer may be formed by reaction of a biomass comprising DNA and/or RNA with one or more crosslinker(s). A crosslinked nucleotide polymers may be formed by a crosslinking reaction including an aza-Michael addition reaction. Crosslinked nucleotide polymers may be present in various forms and compositions and form various articles of manufacture. Crosslinked nucleotide polymers may be used in therapeutic methods, coating methods, and cell-free protein production methods.

Immunobiological products
11173193 · 2021-11-16 ·

The invention relates to a method comprising the step of incubating chitosan in an aqueous solution of an organic carboxylic acid or a salt thereof, a modified chitosan obtainable by the method of the present invention, a hydro colloid, a compound of formula [X]n, a composition comprising the modified chitosan, the hydro colloid or compound according to the present invention, the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in human and/or veterinary medicine and the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in a method of treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis, interdigital phlegmon, trichophytosis, microsporosis, mycosis of skin, allergies, as well as diseases complicated by allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, in particular dermatitis, ear erythema, rhinitis, conjunctivitis, dermatophytosis or warts, in particular Common warts, in a subject and for modulating the immune response in a subject and/or for enhancing reproduction efficiency, preferably reproduction efficiency in animal breeding.

SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS
20220000905 · 2022-01-06 ·

Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.

Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
11167045 · 2021-11-09 ·

Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.

Method of crosslinking glycosaminoglycans

A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.

METHOD FOR PRODUCING A MATERIAL FOR A BONE IMPLANT
20210338896 · 2021-11-04 ·

A material for a bone implant contains: (a) a carrier structure having a surface that has at least one biocompatible material; (b) a matrix covalently bound to the surface; and (c) calcium phosphate embedded in the matrix. A medically acceptable, highly compatible and versatile material can be provided, if the matrix has at least one polysaccharide.

METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS
20230323041 · 2023-10-12 · ·

A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.

Carbohydrate crosslinker

The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.

VARIABLE-SIZE HYDROPHOBICALLY-MODIFIED POLYMERS
20230323096 · 2023-10-12 ·

In various aspects, the invention provides compositions of variable-length hydrophobically-modified polymers. These variable-length hydrophobes decorated along the hydrophilic polymer backbone provide advanced properties and allow for precise control over the behavior of the resulting amphiphilic polymer, including in aqueous solution. Such control allows for enhanced functionality of the amphiphilic polymer relative to standard single-length hydrophobe grafting designs, including for hemostasis.

Hydrophobically modified chitosan compositions
11787922 · 2023-10-17 · ·

Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).